2,138
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Folate receptor-targeted mixed polysialic acid micelles for combating rheumatoid arthritis: in vitro and in vivo evaluation

, , , , , , , & show all
Pages 1182-1191 | Received 22 Mar 2018, Accepted 01 May 2018, Published online: 23 May 2018

References

  • Bader RA, Silvers AL, Zhang N. (2011). Polysialic acid-based micelles for encapsulation of hydrophobic drugs. Biomacromolecules 12:314–20.
  • Bader RA, Wagoner KL. (2010). Modulation of the response of rheumatoid arthritis synovial fibroblasts to proinflammatory stimulants with cyclic tensile strain. Cytokine 51:35–41.
  • Bader RA, Wardwell PR. (2014). Polysialic acid: overcoming the hurdles of drug delivery. Ther Deliv 5:235–7.
  • Drake PM, Nathan JK, Stock CM, et al. (2008). Polysialic acid, a glycan with highly restricted expression, is found on human and murine leukocytes and modulates immune responses. J Immunol 181:6850–8.
  • Elward K, Gasque P. (2003). “Eat me” and “don’t eat me” signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system. Mol Immunol 40:85–94.
  • Feng D, Zhou Y, Xia M, Ma J. (2011). Folic acid inhibits lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-kappa B activation. Inflamm Res 60:817–22.
  • Fernandes AI, Gregoriadis G. (1994). FC41 catalase-polysialic acid conjugates. Eur J Pharm Sci 2:111.
  • Fernandes AI, Gregoriadis G. (1996). Synthesis, characterization and properties of sialylated catalase. Biochim Biophys Acta 1293:90–6.
  • Fernandes AI, Gregoriadis G. (1997). Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim Biophys Acta 1341:26–34.
  • Fernandes AI, Gregoriadis G. (2001). The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 217:215–24.
  • Gregoriadis G, Jain S, Papaioannou I, Laing P. (2005). Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm 300:125–30.
  • Hamad I, Hunter AC, Szebeni J, Moghimi SM. (2008). Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 46:225–32.
  • Jain S, Hreczuk-Hirst DH, Mccormack B, et al. (2003). Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 1622:42–9.
  • Quan L, Zhang Y, Crielaard BJ, et al. (2014). Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8:458–66.
  • Rollett A, Reiter T, Nogueira P, et al. (2012). Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. Int J Pharm 427:460–6.
  • Semple SC, Harasym TO, Clow KA, et al. (2005). Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther 312:1020–6.
  • Wagoner KL, Bader RA. (2012). Evaluation of SV40-transformed synovial fibroblasts in the study of rheumatoid arthritis pathogenesis. Rheumatol Int 32:1885–91.
  • Wang Q, Jiang J, Chen W, et al. (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release 230:64–72.
  • Wang Q, Jiang H, Li Y, et al. (2017). Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy. Biomaterials 122:10–22.
  • Webster R, Didier E, Harris P, et al. (2007). PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9–16.
  • Wilson DR, Zhang N, Silvers AL, et al. (2014). Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis. Eur J Pharm Sci 51:146–56.
  • Yang C, Gao S, Kjems J. (2014). Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. J Mater Chem B 2:8608–15.
  • Yao X, Chen L, Chen X, et al. (2014). Intercellular pH-responsive histidine modified dextran-g-cholesterol micelle for anticancer drug delivery. Colloids Surf B Biointerfaces 121:36–43.
  • Zhang N, Wardwell PR, Bader RA. (2013). Polysaccharide-based micelles for drug delivery. Pharmaceutics 5:329–52.
  • Zhang N, Wardwell PR, Bader RA. (2014). In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs. Pharm Res 31:2326–34.